Information Provided By: 
Fly News Breaks for August 6, 2015
CMRX
Aug 6, 2015 | 14:07 EDT
Brean Capital analyst Jonathan Aschoff raised his price target on Chimerix to $57 from $50 following the company's Q2 report, citing the company's continued progress with brincidofovir for multiple indications. Aschoff, who noted that detailed results for the company's Phase 3 animal trial for smallpox is expected in Q4, keeps a Buy rating on Chimerix shares, which are down 10% to $51.66 in afternoon trading.
News For CMRX From the Last 2 Days
There are no results for your query CMRX
